Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus for CA125-only relapse in ovarian cancer
2008-007925-38Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in epithelial ovarian cancer (EOC), sponsored by HeCOG. Primary endpoint: 6-month clinical progression-free survival. Started Oct 2009; status: terminated.
02
Drugs
temsirolimus
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2008-007925-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007925-38.